Description:
Novel UCL Nanocomposite Polymer
and its Unique Role in the Field of Biomedical Devices
Available For:
Exclusive and Non-Exclusive
licensing
Summary
Our novel nanocomposite polymer (NC)
can uniquely achieve complete tissue and blood compatibility, unlike
conventional medical polymers such as PTFE and Dacron. This offers exciting
possibilities for medical device manufacturers.
The Technology and its
Advantages
The NC is based on silsesquioxane, and exhibits unique
surface properties. It preferentially absorbs and deactivates fibrinogen, thus
preventing activation of the coagulation cascade, inflammation and growth of
tissue capsule.
A new synthesis route allows preparation of the NC so that
it has controlled properties. This is achieved by introducing silsequioxanes as
pendant groups into the backbone of the polymer. Uniquely there is no
degradation by hydrolysis or oxidation. However, variants of the NC can also be
produced so that the controlled degradation will occur, making these
variants suitable candidates for tissue engineering scaffolds. In
addition the NC can be manipulated, for example by attachment of drugs, gene
vectors or other biomolecules relevant to applications.
The NC is not toxic to cells and supports the adhesion and
growth of cells in vitro. Furthermore, the NC inhibits protein absorption by
prolonging the coagulation time. This prevents thrombogenicity and
non-compatibility with blood, which together are the second principle reason
behind failure of material surfaces of medical devices.
A three-year in vitro implantation study in a large animal
model has confirmed in vitro findings that the NC is biocompatible, non-toxic,
and shows no evidence of degradation, inflammation or capsule formation. As the
NC is not drug-based, CE anf FDA approval are more easily achievable and so
offer the manufacturer unique opportunities.
Market Opportunity
The physical properties of the NC are such that it can be
tailored to many specific medical device applications, for example:
- Coronary artery bypass grafts - the NC can be made more
elastic to closely mimic the elasticity of arteries
-Coating of coronary stents - the NC supported adhesion and
growth of cells, including endothelial cells.
-Tissue scaffolds - the NC can be tailor-made to be
degradable under controlled conditions
-Breast implants, condoms and surgical gloves - the NC is
thin and strong and retains its original shape
The NC will allow manufacturers to produce a broad spectrum
of safer, more efficient medical devices and other products.
Intellectual Property Status
A PCT Application has been filed, priority date 20th January
2004. Application Number PCT/GB05/000189
Further Information
Please contact Dr Alexa Smith, Business Manager T: +44
(0)20 7679 9000 E: a.smith@uclb.com
